MD Academy

Nitin Jain, MD - CLL Highlights

Rami Komrokji, MD - MDS Highlights

Panel Discussion

Naveen Pemmaraju, MD - BPDCN Highlights

David McCall, MD - Pediatric Leukemia Highlights

Hagop Kantarjian, MD - CML Highlights

Panel Discussion

Hagop Kantarjian, MD - Current and Future Research Directions in AML

Robert Hasserjian, MD - The Genetic Landscape and Molecular Diagnostics in AML

Panel Discussion

Naval Daver, MD - Optimizing Frontline Therapy for FLT3 Mutated AML Patients Eligible for Intensive

Joshua Zeidner, MD - Genomic Strategies to Guide the Choice of Intensive Treatment Strategies in Non-FLT3m AML

Sanam Loghavi, MD - Diagnostic and Molecular Work-up of Newly Diagnosed AML – The Pathologist’s Perspective

Panel Discussion

Anjali Advani, MD - Philadelphia +ve ALL

Nicholas Short, MD - Ph-ve ALL MRD

Jae Park, MD - New Targets in ALL

Mark Levis, MD - Updates on the Management and Mechanisms of Resistance in R/R FLT3m AML

Charlie Craddock, MD - Emerging Strategies to Improve Outcome of Allo-transplant in AML

Farhad Ravandi, MD - Is There a Role for Intervention at MRD Detection in AML?

Panel Discussion

Courtney DiNardo, MD - How do I use IDH Inhibitors in Frontline and R/R Setting: Single Agent Versus Combinations

Eunice Wang, MD - Current Status and Data with Single Agent Menin Inhibitors

Ghayas Issa, MD - Current Status and Future Directions with Menin Inhibitors in AML

Panel Discussion

Aaron Logan, MD - Integration of Immune-therapy into Frontline ALL

Elias Jabbour, MD - Debate: Chemotherapy-free and TKI Standard of Care in Ph-positive ALL - No Role for Allo

Ibrahim Aldoss, MD - Debate: Chemotherapy-free and TKI Standard of Care in Ph-positive ALL - Yes for Allo

Mark Litzow, MD - AYA ALL

Panel Discussion